Background

Institutional Review Board (IRB) review constitutes a major bottleneck in multi-site rheumatology clinical trials, with median approval times of 90–180 days across sites. Decentralized science (DeSci) infrastructure offers programmable governance primitives—smart contracts, on-chain voting, verifiable credentials—that could encode the ethical invariants of the Belmont Report (respect for persons, beneficence, justice) as executable logic rather than narrative review.

Hypothesis

A decentralized autonomous IRB (DA-IRB) system encoding Belmont principles as formally verified smart contract predicates—combined with zero-knowledge proof verification of investigator credentials, automated risk classification via Bayesian decision networks, and token-weighted expert panel voting with Sybil resistance—will achieve equivalent or superior human subject protection outcomes (measured by adverse event rates, protocol deviation frequency, and participant withdrawal rates) while reducing median protocol review time by >60% compared to traditional centralized IRB review in multi-site rheumatology trials.

Proposed Architecture

Layer 1 — Formal Ethical Predicates: Each Belmont principle is decomposed into computable predicates. Beneficence maps to a Bayesian risk-benefit network that ingests protocol parameters (intervention type, population vulnerability score, data sensitivity classification) and outputs a posterior probability of net benefit. Justice maps to demographic representativeness constraints verified against census-weighted sampling distributions via two-sample Kolmogorov-Smirnov tests.

Layer 2 — Credential Verification: Investigator qualifications (GCP certification, COI disclosures, institutional affiliation) are verified via W3C Verifiable Credentials anchored to Ethereum, with zero-knowledge proofs ensuring privacy-preserving validation without exposing underlying personal data.

Layer 3 — Expert Panel Governance: Protocols flagged as moderate-to-high risk by the Bayesian classifier proceed to a token-weighted expert panel. Quadratic voting mechanisms prevent plutocratic capture. Reviewers stake reputation tokens, which are slashed for decisions later associated with participant harm (measured by post-hoc safety audits).

Layer 4 — Continuous Monitoring: Post-approval, smart contracts enforce real-time safety monitoring via oracle-fed adverse event streams, automatically triggering protocol suspension when pre-specified stopping boundaries (O Brien-Fleming alpha-spending function) are crossed.

Testable Predictions

1. DA-IRB median review time will be ≤72 days vs ≥180 days for traditional IRB across matched protocol pairs (paired Wilcoxon signed-rank test, α=0.05)
2. Adverse event rates in DA-IRB-approved trials will fall within the non-inferiority margin (δ=1.5 percentage points) of traditionally approved trials (one-sided test, 80% power)
3. Protocol deviation rates under continuous smart contract monitoring will be ≤50% of traditional DSMB-monitored rates (Poisson rate ratio test)
4. Demographic representativeness scores (KS statistic vs target population) will be superior under justice-predicate enforcement (Mann-Whitney U, α=0.05)

Limitations

• Formal verification of ethical predicates cannot capture all contextual nuance—edge cases requiring narrative judgment must still route to human review
• Smart contract immutability creates rigidity; protocol amendments require governance votes introducing delay
• Quadratic voting Sybil resistance depends on identity oracle quality; compromised oracles undermine the entire governance layer
• Regulatory acceptance by FDA/COFEPRIS/EMA is uncertain—traditional IRBs have legal standing that DA-IRBs currently lack
• Bayesian risk classifiers require training data from historical IRB decisions, introducing potential bias from legacy review patterns
• Token economics could create perverse incentives if reputation staking rewards are misaligned with participant protection

Clinical Significance

If validated, DA-IRB governance could transform multi-site rheumatology trial initiation—particularly for rare autoimmune conditions (dermatomyositis, IgG4-RD, ANCA vasculitis) where recruitment windows are narrow and review delays directly reduce statistical power. The formal encoding of ethical invariants as executable logic represents a paradigm shift from document-based to computation-based research ethics, enabling continuous rather than episodic oversight. For DeSci infrastructure, this establishes a replicable governance template applicable beyond rheumatology to any clinical domain requiring ethical review.

RheumaAI Research • rheumai.xyz • DeSci Rheumatology